XML 20 R9.htm IDEA: XBRL DOCUMENT v3.22.4
Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Operating activities    
Net loss $ (38,704) $ (28,291)
Adjustments to reconcile net loss to net cash used in operating activities:    
Loss on disposal of assets 1 1
Depreciation 236 451
Stock-based compensation expense 4,256 3,234
Amortization of premiums on short-term investments 632 1,607
Change in fair value of derivative financial instruments—warrants 0 (285)
Release of clinical trial funding commitment 139 2,032
Changes in operating assets and liabilities:    
Other assets (1,148) 166
Accounts receivable and unbilled receivable (236) (215)
Prepaid expenses and other current assets (443) (2,099)
Operating lease right-of-use assets 545 607
Accounts payable and accrued expenses 1,348 719
Operating lease liabilities (404) (811)
Other liabilities (42) (156)
Net cash used in operating activities (33,820) (23,040)
Investing activities    
Capital expenditures (1,006) (205)
Insurance proceeds from casualty loss 114 0
Maturities of short-term investments 76,445 28,391
Purchases of short-term investments (91,233) (174,385)
Sales of short-term investments 53,829 14,751
Net cash provided by (used in) investing activities 38,149 (131,448)
Financing activities    
Proceeds from sale of common stock, preferred stock and warrants, net of expenses of $0 and $813 respectively 0 34,187
Proceeds from exercise of warrants 0 1,263
Proceeds from exercise of options 75 0
Net cash provided by financing activities 75 35,450
Net change in cash and cash equivalents 4,404 (119,038)
Cash and cash equivalents—Beginning of period 11,943 130,981
Cash and cash equivalents—End of period 16,347 11,943
Supplementary disclosure of cash flow activity:    
Cash paid for taxes 2 1
Acquisition of property and equipment included in accounts payable and accrued liabilities 232 6
Supplemental disclosure of non-cash investing and financing activities:    
Accretion of Series A Convertible Preferred Stock dividend 0 24
Cumulative preferred stock dividend adjustment [1] $ (414) $ 0
[1] See Note 2 to the financial statements.